Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.

Kletzl H, Marquet A, Günther A, Tang W, Heuberger J, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmüller H, Wood C, Fischer D, Gerlach I, Heinig K, Bugawan T, Dziadek S, Kinch R, Czech C, Khwaja O.

Neuromuscul Disord. 2019 Jan;29(1):21-29. doi: 10.1016/j.nmd.2018.10.001. Epub 2018 Oct 30.

PMID:
30553700
2.

Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4).

Beach TG, Serrano GE, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbillé AG, Letournel F, Munoz DG, White CL 3rd, Schneider J, Crary JF, Sue LI, Adler CH, Glass MJ, Intorcia AJ, Walker JE, Foroud T, Coffey CS, Ecklund D, Riss H, Goßmann J, König F, Kopil CM, Arnedo V, Riley L, Linder C, Dave KD, Jennings D, Seibyl J, Mollenhauer B, Chahine L; Systemic Synuclein Sampling Study (S4) .

J Neuropathol Exp Neurol. 2018 Sep 1;77(9):793-802. doi: 10.1093/jnen/nly056.

PMID:
30107604
3.

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE.

Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5. Erratum in: Lancet. 2018 Apr 7;391(10128):1356.

PMID:
27156934
4.

Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.

Dengl S, Hoffmann E, Grote M, Wagner C, Mundigl O, Georges G, Thorey I, Stubenrauch KG, Bujotzek A, Josel HP, Dziadek S, Benz J, Brinkmann U.

FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.

5.

Synthesis of antifungal vaccines by conjugation of β-1,2 trimannosides with T-cell peptides and covalent anchoring of neoglycopeptide to tetanus toxoid.

Cartmell J, Paszkiewicz E, Dziadek S, Tam PH, Luu T, Sarkar S, Lipinski T, Bundle DR.

Carbohydr Res. 2015 Feb 11;403:123-34. doi: 10.1016/j.carres.2014.06.024. Epub 2014 Jul 14.

PMID:
25126994
6.

Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.

van Dieck J, Schmid V, Heindl D, Dziadek S, Schraeml M, Gerg M, Massoner P, Engel AM, Tiefenthaler G, Vural S, Stritt S, Tetzlaff F, Soukupova M, Kopetzki E, Bossenmaier B, Thomas M, Klein C, Mertens A, Heller A, Tacke M.

Chem Biol. 2014 Mar 20;21(3):357-68. doi: 10.1016/j.chembiol.2013.12.018. Epub 2014 Feb 13.

7.

PK modulation of haptenylated peptides via non-covalent antibody complexation.

Hoffmann E, Konkar A, Dziadek S, Josel HP, Conde-Knape K, Kropp H, Kling L, Stubenrauch K, Thorey I, Dengl S, Brinkmann U.

J Control Release. 2013 Oct 10;171(1):48-56. doi: 10.1016/j.jconrel.2013.06.021. Epub 2013 Jun 22.

8.

Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis.

Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE.

PLoS One. 2012;7(4):e35106. doi: 10.1371/journal.pone.0035106. Epub 2012 Apr 26.

9.

Bispecific digoxigenin-binding antibodies for targeted payload delivery.

Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, Lammens A, Scheuer W, Hoffmann E, Mundigl O, Brinkmann U.

Proc Natl Acad Sci U S A. 2011 May 17;108(20):8194-9. doi: 10.1073/pnas.1018565108. Epub 2011 May 2.

10.

Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis.

Xin H, Dziadek S, Bundle DR, Cutler JE.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13526-31. doi: 10.1073/pnas.0803195105. Epub 2008 Aug 25.

11.
12.

Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy.

Becker T, Dziadek S, Wittrock S, Kunz H.

Curr Cancer Drug Targets. 2006 Sep;6(6):491-517. Review.

PMID:
17017874
13.

Synthesis and structural model of an alpha(2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions.

Dziadek S, Griesinger C, Kunz H, Reinscheid UM.

Chemistry. 2006 Jun 23;12(19):4981-93.

PMID:
16642533
14.

A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.

Dziadek S, Hobel A, Schmitt E, Kunz H.

Angew Chem Int Ed Engl. 2005 Nov 25;44(46):7630-5. No abstract available.

PMID:
16247815
15.

Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin.

Dziadek S, Kowalczyk D, Kunz H.

Angew Chem Int Ed Engl. 2005 Nov 25;44(46):7624-30. No abstract available.

PMID:
16247814
17.

Supplemental Content

Loading ...
Support Center